The Top 5 Biosimilars Articles for the Week of August 7

The Center for Biosimilars Staff

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of August 7, 2017.

Transcript

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of August 7.

Number 5: Some health plans are telling consumers that they must purchase brand name drugs, even when cheaper generics are available, leading to higher out-of-pocket costs for patients.

Number 4: The FDA’s Office of Surveillance has released findings from an inspection of Biocon’s troubled manufacturing facility in Bangalore. The investigators found 10 problems, including issues with labeling and sterility.

Number 3: A recent study comparing biosimilar GP2013 to both EU- and US-approved rituximab shows 3-way PK and PD equivalence in patients with rheumatoid arthritis.

Number 2: FDA Commissioner, Dr Scott Gottlieb, has formed a new working group within the agency. The group will focus on increasing generic competition.

And Number 1: Pharmacist Kyle Skiermont, COO of Fairview Pharmacy Services, discusses his experience with payers and healthcare providers as they prepare for the impact of biosimilar drugs and non-medical switching.

Finally, last week, our newsletter asked you to share your thoughts on whether interchangeability will be important to the uptake of biosimilars. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.

To read these articles and more, visit centerforbiosimilars.com.